REG - Burning Rock Biotech - BNR and BI Achieved a Master Service Agreement

Burning Rock BiotechAnnouncement

30/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231030:nRSd6877Ra&default-theme=true

RNS Number : 6877R  Burning Rock Biotech Limited  30 October 2023

Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in
Oncology Companion Diagnostics

 

GUANGZHOU, China, October 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech
Limited (NASDAQ: BNR and LSE: BNR, the "Company" or "Burning Rock") is pleased
to announce that the Company and Boehringer Ingelheim officially have signed
the Master Service Agreement (MSA) in the field of oncology companion
diagnostics. This agreement aims to provide Chinese patients with safer, more
efficient, and precise treatment options and diagnostic methods, thereby
promoting innovation and development in cancer treatment. This partnership
will primarily focus on advancing the clinical trials related to Boehringer
Ingelheim's MDM2-p53 antagonist, brigimadlin (BI 907828), and the development
of companion diagnostic products in China.

 

Brigimadlin is a novel small-molecule drug developed by Boehringer Ingelheim
as a MDM2-p53 antagonist. Recently, brigimadlin received approval from the
China National Medical Products Administration (NMPA) for its Phase II
clinical trial, known as Brightline-2, targeting locally advanced or
metastatic MDM2-amplified, TP53 wild-type solid tumors. It offers new
treatment options for patients with MDM2-amplified, TP53 wild-type cancers,
such as Biliary Tract Carcinoma (BTC), and opens up a "pan-tumor" treatment
approach targeting the MDM2-p53 axis. Previous Phase I studies demonstrated
anti-tumor activity for brigimadlin across various solid tumors, with
particularly promising clinical efficacy observed in BTC patients.

 

With the formal approval of the Brightline-2 clinical trial, the safety and
efficacy of brigimadlin will undergo further validation. Burning Rock will
leverage its dual-center, internationally accredited laboratory, a global
companion diagnostics registration pipeline, a comprehensive biomarker
development solution for drug research, and its extensive experience in
clinical projects and companion diagnostics development and submissions,
providing comprehensive support for the research and development of the
innovative drug brigimadlin and the development and validation of companion
diagnostic assays, offering new hope for patients with hard-to-treat and rare
cancers in China.

 

Mr. Yusheng Han, Founder and CEO of Burning Rock, expressed, "We are delighted
to establish a deep collaboration in companion diagnostics with Boehringer
Ingelheim. Burning Rock has a comprehensive layout and supports companion
diagnostics development with a global perspective for pharmaceutical
companies. We believe that by integrating the resources and expertise of both
parties in the field of oncology diagnosis and treatment, this collaboration
will set a standardized and high-quality benchmark for the co-development of
companion diagnostics for new anti-cancer drugs. We look forward to achieving
more significant breakthroughs in this collaboration and providing more
precise treatment options for Chinese cancer patients."

 

 

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), whose mission is to
guard life via science, focuses on the application of next generation
sequencing (NGS) technology in the field of precision oncology. Its business
consists of i) NGS-based therapy selection testing for late-stage cancer
patients, and ii) cancer early detection, which has moved beyond
proof-of-concept R&D into the clinical validation stage.

 

For more information about Burning Rock, please visit: www.brbiotech.com.

 

Enquiries:

Contact: IR@brbiotech.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRGZMFGNGKGFZG